Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma

European Journal of Nuclear Medicine

Volumn 26, Issue 1, 1999, Pages 31-38

  Kotzerke, Jörg ^a   Guhlmann, Albrecht ^b   Moog, Florian ^b   Frickhofen, Norbert ^b   Reske, Sven N ^b  

^a UNIVERSITY OF ULM   (Germany)

^b NONE

Author keywords

Attenuation correction; Fluorine 18 fluorodeoxyglucose positron emission tomography; Hodgkin's disease; Lymphoma; Staging

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE;

ABDOMEN; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER STAGING; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; LIVER; LUNG; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; NONHODGKIN LYMPHOMA; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; SCHOOL CHILD; SOFT TISSUE; SPLEEN;

ADOLESCENT; ADULT; CHILD; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033024059     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050356     Document Type: Article

References (28)

1. 1. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan CN, Wolf AP, Zahinski SV. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
2. 2. Larson SM, Weiden PL, Grunbaum Z, Kaplan HG, Rasey JS, Graham MM, Sale GE, Harp GD, Williams DL. Positron imaging feasibility studies. II: Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms: concise communication. J Nucl Med 1981; 22: 875-879.
3. 3. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, Coleman RE. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34: 567-575.
4. 4. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
5. 5. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475-481.
6. 6. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16: 603-609.
7. 7. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116.
8. 8. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, Kuyama J, Maruno H, Arimizu N. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
9. 9. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
10. 10. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
11. 11. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, Arimizu N. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
12. 12. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
13. 13. Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, Phelps ME. Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med 1992; 33: 1191-1199.
14. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
15. 15. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997; 24: 1091-1098.
16. 16. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
17. 17. Rosenberg SA, Berard CW, Brown BW, et al. National Cancer Institute sponsored study of classification on non-Hodgkin's lymphomas: summary and description of a working formulation for clinical use. Cancer 1982; 49: 2112-2135.
18. 18. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994; 21: 930-936.
19. 19. Diederichs CG, Glatting G,0 Reske SN. Iterative image reconstruction reduces apparent tumor distortion [letter; comment]. Radiology 1997; 204: 279.
20. 20. Römer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, Schwaiger M. Positron emission tomography in non-Hodgkin's Lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
21. 21. Bergstrom M, Litton J, Eriksson L, Bohm C, Blomqvist G. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr 1982; 6: 365-372.
22. 22. Hooper PK, Meikle SR, Eberl S, Fulhum MJ. Validation of postinjection transmission measurements for attenuation correction in neurological FDG-PET studies. J Nucl Med 1996; 37: 128-136.
23. 23. Knesaurek K, Machac J, Vallabhajosula S, Buchsbaum MS. A new iterative reconstruction technique for attenuation correction in high-resolution positron emission tomography. Eur J Nucl Med 1996; 23: 656-661.
24. 24. Meikle SR, Bailey DL, Hooper PK, Eberl S, Hutton BF, Jones WF, Fulton RR, Fulham MJ. Simultaneous emission and transmission measurements for attenuation correction in whole-body PET. J Nucl Med 1995; 36: 1680-1688.
25. 25. Lodge MA, Badawi RD, Marsden PK. A clinical evaluation of the quantitative accuracy of simultaneous emission/transmission scanning in whole-body positron emission tomography. Eur J Nucl Med 1998; 25: 417-423.
26. 26. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26: 308-314.
27. 27. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441-446.
28. 28. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. Am J Roentgenol 1997; 169: 1675-1680.